



US009789152B2

(12) **United States Patent**
Hayer et al.

(10) **Patent No.:** **US 9,789,152 B2**
(45) **Date of Patent:** ***Oct. 17, 2017**

(54) **COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH**

FOREIGN PATENT DOCUMENTS

RO 80051 A2 10/1982

(71) Applicant: **KIDNEY STONE RESEARCH COMPANY, INC.**, Fort Lauderdale, FL (US)

OTHER PUBLICATIONS

(72) Inventors: **Gregory K. Hayer**, Fort Lauderdale, FL (US); **Brendan Magrab**, Westfield, NJ (US); **Henry R. Wolfe, Jr.**, Glenmoore, PA (US)

“Highlights of Prescribing Information:Urocit-K (Potassium Citrate)”;Mission Pharmacal Company; Dec. 2009; 2 pages.
“Kidney stones”;Magnesium online resource center;2007-2008;[retrieved Aug. 19, 2015 from http://www.mg12.info/articles/kidney-stones.html]; 2 pages.

(73) Assignee: **KIDNEY STONE RESEARCH COMPANY, INC.**, Fort Lauderdale, FL (US)

Abirami J et al.; “Evaluation of Toxicity Profiles of *Musa paradisiaca* L (Pseudostem) Juice”; International Journal of Pharmacy and Pharmaceutical Sciences; vol. 6, Sup. 1; 2014; pp. 9-11.

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Devi et al.; “Biochemical Effects in Normal and Stone Forming Rats Treated With the Ripe Kernel Juice of Plantain (*Musa paradisiaca*)”; Ancient Science of Life, vol. XII,Nos. 3 & 4; 1993; pp. 451-461.

This patent is subject to a terminal disclaimer.

Duan; “Changes in urinary nanocrystallites in calcium oxalate stone formers before and after potassium citrate intake”; International Journal of Nanomedicine,vol. 8; 2013; pp. 909-918.

(21) Appl. No.: **15/487,735**

Ebisuno et al.; “Results of long-term rice bran treatment on stone recurrence in hypercalciuric patients”; Br J Urol.; vol. 67, No. 3; 1991; pp. 237-240 (Abstract Only).

(22) Filed: **Apr. 14, 2017**

Ebisuno et al.; “Rice-bran Treatment for Calcium Stone Formers with Idiopathic Hypercalciuria”; British Journal of Urology; vol. 58, No. 6; 1986; pp. 592-595 (Abstract Only).

(65) **Prior Publication Data**

US 2017/0216388 A1 Aug. 3, 2017

Grases et al.; “Influence of Concomitant Food Intake on the Excretion of Orally Administered myo-Inositol Hexaphosphate in Humans”; J Med Food vol. 9, No. 1; 2006; pp. 72-76.

Related U.S. Application Data

(60) Continuation of application No. 15/266,464, filed on Sep. 15, 2016, now Pat. No. 9,623,066, which is a division of application No. 15/059,644, filed on Mar. 3, 2016, now Pat. No. 9,492,491, which is a continuation-in-part of application No. 14/960,692, filed on Dec. 7, 2015, which is a continuation of application No. 14/845,612, filed on Sep. 4, 2015, now Pat. No. 9,233,135.

Jha U et al.;“Pharmacological Screening of *Musa Paradisiaca* Linn Against Ethylene Glycol Induced Renal Calculi”; Interntional Journal of Research in Ayurveda & Pharmacy, vol. 2, No. 3; 2011; pp. 995-998.

(51) **Int. Cl.**

A61K 36/00 (2006.01)
A61K 36/88 (2006.01)
A61K 31/194 (2006.01)
A61K 31/6615 (2006.01)
A61K 31/4415 (2006.01)
A61K 9/00 (2006.01)

Kalpana et al. ; “Inhibition of Calcium Oxalate Crystallization In Vitro by Extract of Banana Cultivar Monthan”; International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, No. 4; 2013; pp. 649-653.

(52) **U.S. Cl.**

CPC **A61K 36/88** (2013.01); **A61K 9/0053** (2013.01); **A61K 31/194** (2013.01); **A61K 31/4415** (2013.01); **A61K 31/6615** (2013.01)

Khan et al.;“Antiurolithic activity of *Origanum vulgare* is mediated through multiple pathways”; BMC Complementary and Alternative Medicine; vol. 11, No. 96; 2011; 16 pages.

(58) **Field of Classification Search**

None
See application file for complete search history.

Lindberg et al.; “Magnesium Bioavailability from Magnesium Citrate and Magnesium Oxide”; Journal of the American College of Nutrition, vol. 9, No. 1; 1990; pp. 48-55.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2009/0068255 A1 3/2009 Yu et al.
2013/0302448 A1 11/2013 Parc
2013/0337057 A1 12/2013 Patankar
2014/0272068 A1 9/2014 Prakash et al.

Massey; “Magnesium therapy for nephrolithiasis”; Magnesium Research, vol. 18, No. 2; 2005; pp. 123-126.

McNally et al.; “Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet”;Pediatrics; vol. 124, No. 2; Aug. 2009; pp. 300-304 (Abstract Only).

Ogawa et al.; “Effects of sodium citrate, potassium citrate, and citric acid in preventing experimental calcium oxalate urolithiasis in rats”; Acta Urol. Jpn.; vol. 33, No. 11; 1987; pp. 1772-1777.

Patankar et al.;“A Prospective,Randomized,Controlled Study to Evaluate the Efficacy & Tolerability of Ayurvedic Formulation *Varuna* and *Banana Stem*” in the Management of Urinary Stones;J. of Alternative & Complementary Medicine;vol. 14, No. 10;2008;4pgs.

(Continued)

Primary Examiner — Qiuwen Mi

(74) *Attorney, Agent, or Firm* — Cantor Colburn LLP

(57) **ABSTRACT**

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

19 Claims, 78 Drawing Sheets